Overview

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

Status:
Active, not recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people with HIV (PWH) with multi-drug resistance (MDR).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Gilead Sciences